EGFR and non-small cell lung carcinoma: The drugs significantly improve the median progression‐free survival (PFS) from 4.6 to 13.1 months in patients with NSCLC with EGFR exon 21 L858 mutation (EGFRL858R) or exon 19 deletion (EGFRdel19) 24.